S&P Global Inc (SPGI) Stock Price Today
Aura AI Summary
Key Stats
- $119.24BMarket Cap
- 1,284,500Volume
- FinancialsSector
- $517.9252W High
- $370.4252W Low
- 121 DaysTypical Hold Time
- $130.73BEnterprise Value
- 0.96%Div Yield
- 0% Sell | 100% BuyTrading Activity
Track S&P Global Inc (SPGI) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, S&P Global Inc has traded between a low of $370.42 and a high of $517.92, highlighting its annual price range. Buy and sell S&P Global Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Most Recent News
Stocks JAGX, GRML, and VKTX soar on FDA approvals, biotech data, and mineral interest.
Jaguar Health (JAGX) surged over 1,150% after the FDA granted fee waivers for its drugs Mytesi and Canalevia-CA1, signaling regulatory support. Greenland Mines (GRML) rose nearly 50% amid growing investor interest linked to U.S.-Greenland security de...

Market downturn hits top stocks: New Fortress Energy falls nearly 25%, quantum and tech stocks also slide.
The market experienced a downturn with significant losses among key stocks. New Fortress Energy dropped 24.7% amid ongoing volatility in energy sectors, while Xanadu Quantum Technologies fell 21.7% reflecting sensitivity in quantum stocks to commerci...

Fulcrum Therapeutics faces investigation after stock halves due to halted sickle cell drug program.
Fulcrum Therapeutics announced it stopped development of its sickle cell disease drug, pociredir, following FDA concerns about cancer risks linked to similar drugs. This led to a 51% drop in its stock price. Kaplan Fox & Kilsheimer LLP is investigati...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.